Pesquisar
Biogen Inc
BIIBAdicionar à lista de desejos
250.690USD
-3.150-1.24%
Fechamento 10-23 16:00（ET）
37.04BValor de mercado
26.84P/L TTM
Após o expediente 16:01 (ET)251.060USD+0.200+0.08%
Após o expediente 16:01 (ET)Desempenho da Receita de Biogen Inc (BIIB)
Atualizado em: 30 de jun de 2026No ano passado, Biogen Inc gerou US$ 2.15B em seu segmento de melhor desempenho, Spinal Muscular Atrophy-SPINRAZA. A região United States teve a maior contribuição, com US$ 3.73B no período. No último trimestre, Biogen Inc registrou receita de US$ 601.70M no período encerrado em 2026-06-30, proveniente principalmente do segmento Spinal Muscular Atrophy-SPINRAZA. A região United States teve a maior contribuição, com receita de US$ 3.91B.
Por Empresa
Receita
Proporção
Anual
Anual
Trimestral
Spinal Muscular Atrophy-SPINRAZA
MS product revenues-TYSABRI
MS product revenues-Fumarate
MS product revenues-Interferon
Biosimilar product revenues-BENEPALI
Other-FUMADERM
Biosimilar product revenues-IMRALDI
Alzheimer's collaboration revenue
Biosimilar product revenues-FLIXABI
Biosimilars product Revenues -BYOOVIZ
MS product revenues-FAMPYRA
Alzheimer's disease:ADUHELM
Product revenues, net
Revenues from anti-CD20 therapeutic programs
Other revenues
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Spinal Muscular Atrophy-SPINRAZA
2.15B(29.52%)
1.99B(27.33%)
1.80B(24.88%)
1.79B(22.45%)
1.91B(21.53%)
2.05B(19.19%)
--(--)
MS product revenues-TYSABRI
1.67B(22.82%)
1.72B(23.58%)
1.88B(25.90%)
2.03B(25.43%)
2.06B(23.32%)
1.95B(18.20%)
--(--)
MS product revenues-Fumarate
1.43B(19.55%)
1.60B(21.93%)
1.59B(21.92%)
2.00B(25.00%)
2.36B(26.70%)
3.91B(36.53%)
--(--)
MS product revenues-Interferon
945.60M(12.96%)
968.00M(13.31%)
1.11B(15.26%)
1.31B(16.34%)
1.57B(17.70%)
1.88B(17.56%)
--(--)
Biosimilar product revenues-BENEPALI
453.20M(6.21%)
479.10M(6.59%)
438.80M(6.06%)
441.00M(5.52%)
498.30M(5.63%)
481.60M(4.50%)
--(--)
Other-FUMADERM
197.20M(2.70%)
82.50M(1.13%)
7.80M(0.11%)
8.20M(0.10%)
11.00M(0.12%)
12.20M(0.11%)
--(--)
Biosimilar product revenues-IMRALDI
190.20M(2.61%)
213.10M(2.93%)
222.10M(3.06%)
224.50M(2.81%)
233.40M(2.64%)
216.30M(2.02%)
--(--)
Alzheimer's collaboration revenue
177.70M(2.44%)
59.90M(0.82%)
--(--)
--(--)
--(--)
--(--)
--(--)
Biosimilar product revenues-FLIXABI
52.60M(0.72%)
63.20M(0.87%)
77.40M(1.07%)
81.30M(1.02%)
99.40M(1.12%)
97.90M(0.92%)
--(--)
Biosimilars product Revenues -BYOOVIZ
33.10M(0.45%)
37.70M(0.52%)
31.70M(0.44%)
4.30M(0.05%)
--(--)
--(--)
--(--)
MS product revenues-FAMPYRA
1.40M(0.02%)
71.70M(0.99%)
90.50M(1.25%)
96.60M(1.21%)
105.20M(1.19%)
103.10M(0.96%)
--(--)
Alzheimer's disease:ADUHELM
--(--)
--(--)
4.00M(0.06%)
4.80M(0.06%)
3.00M(0.03%)
--(--)
--(--)
Product revenues, net
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
11.38B(79.15%)
Revenues from anti-CD20 therapeutic programs
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
2.29B(15.93%)
Other revenues
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
707.70M(4.92%)
Por Região
Receita
Proporção
Anual
Anual
Trimestral
United States
Rest of world
United states-Revenues from anti-CD20 therapeutic
Rest of World-Other revenues
Rest of World
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
United States
3.73B(37.67%)
3.30B(34.08%)
3.14B(31.94%)
3.47B(34.10%)
3.81B(34.65%)
5.90B(43.88%)
6.71B(46.67%)
Rest of world
3.57B(36.11%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
United states-Revenues from anti-CD20 therapeutic
1.86B(18.81%)
1.75B(18.09%)
1.69B(17.18%)
1.70B(16.72%)
1.66B(15.10%)
1.98B(14.71%)
2.29B(15.94%)
Rest of World-Other revenues
732.90M(7.41%)
652.60M(6.74%)
899.30M(9.14%)
485.10M(4.77%)
476.30M(4.34%)
774.60M(5.76%)
707.70M(4.92%)
Rest of World
--(--)
3.98B(41.09%)
4.11B(41.74%)
4.52B(44.41%)
5.04B(45.91%)
4.79B(35.64%)
4.67B(32.47%)